In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
|Podcasts|September 4, 2019
Mapping Multiple Myeloma Advances in NYC
Author(s)Onclive Team
We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.
Advertisement
We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. We met with experts from Mount Sinai Hospital to gather updates on emerging treatment strategies in multiple myeloma, including headway made with CAR T-cell therapies, the role of genomics, the shift toward personalized medicine, and progress made with maintenance therapies.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
FDA Flashback: Breast Cancer Decisions and News From June 2026
3
Revisit Every OncLive On Air Episode From June 2026
4
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
5